Industry News
Excerpt from the Press Release: CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been dosed in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult…
Read MoreThree-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and reduces need for IOP-lowering medications in open-angle glaucoma patients Excerpt from the Press Release: MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing…
Read MoreExcerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 /PRNewswire/ — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) today announced that ALX Oncology’s next generation CD47 blocker, evorpacept, has been selected for…
Read MorePhase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases Excerpt from the Press Release: TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2022 / CureVac N.V. (Nasdaq:CVAC),…
Read MoreDiagnostics enable the detection of the monkeypox virus in humans Excerpt from the Press Release: SAN DIEGO, Aug. 18, 2022 /PRNewswire/ — CorDx, a global leader in the development, manufacturing, and distribution of diagnostics and medical devices, was recently granted a CE Mark certificate for two of the company’s monkeypox diagnostic tests. The CE Mark,…
Read MoreNew clinical data demonstrate high and sustained geometric mean fold rises (GMFR) in neutralizing antibodies against all evaluated Omicron variants Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and…
Read MoreFirst in human study demonstrates positive safety and tolerability profile for MapLight’s M1/M4 muscarinic agonist therapy Excerpt from the Press Release: SAN FRANCISCO, Aug. 18, 2022 /PRNewswire/ — MapLight Therapeutics today announced it has completed its Phase 1 clinical trial evaluating ML-007, the second clinical compound developed using the MapLight platform. ML-007 is an M1/M4…
Read MoreExcerpt from the Press Release: Valo’s Opal Computational Platform™ being used to select a patient subset within non-proliferative diabetic retinopathy patients at high risk of progressing toward vision-threatening disease BOSTON, Aug. 18, 2022 /PRNewswire/ — Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and…
Read MoreExcerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in…
Read MoreBEACON study will evaluate bitopertin as a potential disease-modifying treatment for patients with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP) Key assessments include changes in protoporphyrin IX levels, safety, tolerability and measures of photosensitivity; preliminary data expected by 1H 2023 Excerpt from the Press Release: WATERTOWN, Mass., Aug. 10, 2022 /PRNewswire/ — Disc Medicine, a clinical-stage biotechnology…
Read More